128 related articles for article (PubMed ID: 37671741)
1. Lenalidomide maintenance in Myeloma - a goldilocks problem?
Ng Liet Hing M; Khot A
Leuk Lymphoma; 2023 Oct; 64(10):1611-1614. PubMed ID: 37671741
[No Abstract] [Full Text] [Related]
2. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
Modi D; Chi J; Kim S; Ayash L; Alavi A; Kin A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2020 Aug; 61(8):1877-1884. PubMed ID: 32270725
[TBL] [Abstract][Full Text] [Related]
5. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P
Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560
[TBL] [Abstract][Full Text] [Related]
6. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
8. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Cherniawsky HM; Kukreti V; Reece D; Masih-Khan E; McCurdy A; Jimenez-Zepeda VH; Sebag M; Song K; White D; Stakiw J; LeBlanc R; Reiman A; Aslam M; Louzada M; Kotb R; Gul E; Atenafu E; Venner CP
Haematologica; 2021 Jun; 106(6):1733-1736. PubMed ID: 33054120
[No Abstract] [Full Text] [Related]
9. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Roussel M; Hebraud B; Hulin C; Perrot A; Caillot D; Stoppa AM; Macro M; Escoffre M; Arnulf B; Belhadj K; Karlin L; Garderet L; Facon T; Guo S; Weng J; Dhanasiri S; Leleu X; Moreau P; Attal M
Leuk Lymphoma; 2020 Jun; 61(6):1323-1333. PubMed ID: 32090636
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO
Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.
Mancuso K; Tacchetti P; Pantani L; Rocchi S; Rizzello I; Caratozzolo I; De Cicco G; Fusco A; Testoni N; Terragna C; Marzocchi G; Martello M; Borsi E; Dozza L; Cavo M; Zamagni E
Bone Marrow Transplant; 2020 Sep; 55(9):1865-1867. PubMed ID: 32103147
[No Abstract] [Full Text] [Related]
14. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.
Mohan M; Janz S; Brazauskas R; Dwinell MB; Teng BQ; Yun G; Dong J; Pasquini MC; Giralt S; Landau H; Stadtmauer E; Krishnan A; D'Souza A
Bone Marrow Transplant; 2023 Aug; 58(8):953-955. PubMed ID: 37149674
[No Abstract] [Full Text] [Related]
15. Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I; Gertz M
Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P
Leukemia; 2023 Jul; 37(7):1521-1529. PubMed ID: 37316728
[TBL] [Abstract][Full Text] [Related]
17. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]